Osteoarthritis
Not recruitingStudy on the Effects of RHH646 for Patients with Knee Osteoarthritis
- Disease:Osteoarthritis
- Substances:Rhh646
Germany- Participants:18–64 years · 65+ years
- Substances:Rhh646
- Sponsor:Novartis Pharma AG
Rare diseases
Investigational molecules
Locations
Back to Germany1 clinical trial in Langenhorn Hamburg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)
GermanyThe busiest research cities in the country
What the registry says about research in the country
Innovative research focusing on psoriatic arthritis treatments, evaluating new therapeutic approaches for patients who haven't received biological medicines previously.
These trials aim to expand treatment options for patients with active psoriatic arthritis by testing different therapeutic agents.
Clinical investigations of guselkumab for treating active psoriatic arthritis, focusing on reducing disease symptoms and improving patient outcomes.
Research centers on evaluating advanced therapies for managing inflammatory joint conditions.
Groundbreaking research into knee osteoarthritis treatment, investigating cartilage regeneration potential through innovative therapeutic approaches.
The research focuses on developing treatments that could potentially restore joint function and improve patient mobility.
Tell us about your condition – we search every trial in Europe and connect you with the right site.